Rare Diseases Feature Prominently In Q2 2013 Biopharma Financing
Executive Summary
Rare disease biopharmas featured prominently in the Q2 2013 financing landscape in not just venture funding, but across several financing types. These companies were involved in 15 financings (including four Series A rounds) and brought in a collective $632 million.